재스퍼 테라퓨틱스(JSPR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.79 (-8.46%), 시가총액 $0.02B, 52주 범위 $0.67 ~ $6.82.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
재스퍼 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
재스퍼 테라퓨틱스의 현재 주가는 $0.79 (-8.46%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
재스퍼 테라퓨틱스의 시가총액은 약 $0.02B입니다.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidat